Patents by Inventor Annette Prento

Annette Prento has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6416756
    Abstract: Modified enzymes are prepared for use in skin care products by covalently coupling to the enzymes from 4 to 70 polymeric molecules with or without a linker such as a triazine ring. Molecular weight of the polymeric molecules may be from 1 to 35 kDa and of the enzymes from 15 to 100 kDa. The number and weight of polymeric molecules coupled is balanced with the weight and/or surface area of the enzymes. Enzymes include proteases such as subtilisins, lipases and oxidoreductases such as laccases and superoxide dismutase, and polymeric molecules include polysaccharides such as dextran or pullulan and polyalkylene oxides such as polyethylene glycol. The polymeric molecules may be coupled to the enzymes at the N-terminal amino group and/or lysine residues, and preferably at a position more than 5 Å from the active site of the enzymes. A preferred modified enzyme is a protease having from 5 to 13 coupled polymeric molecules.
    Type: Grant
    Filed: February 5, 1998
    Date of Patent: July 9, 2002
    Assignee: Novozymes A/S
    Inventors: Arne Agerlin Olsen, Annette Prento
  • Patent number: 6106828
    Abstract: The present invention provides polypeptide conjugates with reduced allergenicity comprising a polymeric carrier molecule having two or more polypeptide molecules coupled thereto. The invention also provides methods for producing the conjugates, compositions comprising the conjugates, and the use of the conjugates in industrial applications, including personal care products and detergent compositions.
    Type: Grant
    Filed: July 28, 1998
    Date of Patent: August 22, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Bisgard-Frantzen, Arne Agerlin Olsen, Annette Prento
  • Patent number: 5206144
    Abstract: The concentration of glycated hemoglobin, HbA.sub.1c, in hemoglobin from diabetic patients is regarded as a useful means of assessing the adequacy of diabetes control. This invention comprises a monoclonal antibody which, due to its specific binding of HbA.sub.1c, can be used for the determination of HbA.sub.1c in the absence of prior denaturation, in blood samples by such analytical methods as radioimmuno assay or enzyme-linked immunosorbent assay. The invention also comprises hybridoma cell lines which produce monoclonal antibodies of the invention.
    Type: Grant
    Filed: October 30, 1990
    Date of Patent: April 27, 1993
    Assignee: Novo Industri A/S
    Inventors: Jesper Zeuthen, Annette Prento, Viggo Kruse